Idiopathic MCD and intermediate forms (clinical picture falling between UCD and iMCD) are treated with anti-IL-6 treatment, siltuximab (monoclonal antibody against IL-6) or tocilizumab (monoclonal antibody inhibiting IL-6-receptor). Here, IL6 is linked to urea cycle disorder.